Cellectar Biosciences Inc (CLRB)

[Crusader]

Maybe, but the REAL NEWS in a few days

should be about non-Hodgkin lymphoma (DLBCL) results in the PHASE 3 clinical trials of CLRB’s CLR-131:


Diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults,[1] with an annual incidence of 7–8 cases per 100,000 people per year in the USA and the UK.[2][3] This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,[3] though it can also occur in children and young adults in rare cases.[4] DLBCL is an aggressive tumor which can arise in virtually any part of the body,[5] and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms—fever, weight loss, and night sweats.[6]


This weekend could be the stage for news, after today’s announcement that CLR-131 was granted orphan drug designation by the European Commission:

Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
BY GlobeNewswire
— 8:00 AM ET 09/10/2019
FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (CLRB), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral presentation at the upcoming European Society for Medical Oncology ESMO Congress 2019 being held in Barcelona, Spain from September 27 – October 1, 2019.
The presentation will focus on the nature of the patient population and the activity of CLR 131 in these heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).